Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Other Accumulated Expenses (2024 - 2025)

Maze Therapeutics has reported Other Accumulated Expenses over the past 2 years, most recently at $4.3 million for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 46.73% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 46.73% year-over-year, with the annual reading at $4.3 million for FY2025, 46.73% up from the prior year.
  • Other Accumulated Expenses was $4.3 million for Q4 2025 at Maze Therapeutics, up from $59000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $4.9 million in Q2 2025 and troughed at $59000.0 in Q3 2025.